Literature DB >> 6813385

Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model.

A U Gerber, A P Vastola, J Brandel, W A Craig.   

Abstract

The therapeutic failure of aminoglycosides in leukopenic mice was studied. Pseudomonas aeruginosa isolated from experimentally infected leukopenic mice was analyzed for susceptibility to gentamicin. Bacterial population analyses were performed before, during, and after therapy with high doses of gentamicin. Inocula from numerous strains, including P. aeruginosa strain ATCC 27853, harbored slowly growing aminoglycoside-resistant subpopulations. In leukopenic mice (in contrast to normal mice) receiving gentamicin, the breakthrough growth of these subpopulations occurred 6 hr after treatment. Resistance to gentamicin reversed in vivo when gentamicin treatment was stopped. The emergence of gentamicin-resistant subpopulations was successfully suppressed by a combined treatment regimen of gentamicin and ticarcillin. Gentamicin-ticarcillin synergy in these infections is due, in part, to antimicrobial suppression of slowly growing aminoglycoside-resistant subpopulations of bacteria.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6813385     DOI: 10.1093/infdis/146.5.691

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  42 in total

Review 1.  Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models.

Authors:  A Dalhoff; U Ullmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

2.  Pharmacodynamics and alternative antimicrobial dosing regimens.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1995-01

3.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 4.  Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance.

Authors:  C Andrew DeRyke; Su Young Lee; Joseph L Kuti; David P Nicolau
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.

Authors:  D Andes; A Forrest; A Lepak; J Nett; K Marchillo; L Lincoln
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling.

Authors:  D Andes; A Lepak; J Nett; L Lincoln; K Marchillo
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 7.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

8.  Animal models in the evaluation of antimicrobial agents.

Authors:  O Zak; T O'Reilly
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

9.  Once-daily dosing of aminoglycosides.

Authors:  J Blaser; C König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

10.  Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve.

Authors:  J E Tisdale; M T Pasko; J M Mylotte
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.